Spectra A novel diagnostic device to improve retinal imaging
Health Intelligence provide medical software as diagnostic medical devices. We have developed retinal (fundus) photograph analytical software - Spectra, complemented by the lower cost, standalone and portable Spectra Retineye. Spe...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
Eye Light
Eye fundus colour images enhancement service for Diabetic Re...
71K€
Cerrado
iScan
Automated retinal scans for early detection of diabetic eye...
4M€
Cerrado
MERLIN
Multi modal multi scale retinal imaging
6M€
Cerrado
TIN2013-46751-R
ANALISIS DE IMAGEN DE FONDO DE OJO PARA CRIBADO AUTOMATICO D...
169K€
Cerrado
RETINAL
Retinal imaging prevention and early detection of chronic di...
2M€
Cerrado
iScan
Automated retinal scans for early detection of diabetic eye...
71K€
Cerrado
Información proyecto Spectra
Duración del proyecto: 6 meses
Fecha Inicio: 2015-06-18
Fecha Fin: 2015-12-31
Líder del proyecto
HEALTH INTELLIGENCE LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Health Intelligence provide medical software as diagnostic medical devices. We have developed retinal (fundus) photograph analytical software - Spectra, complemented by the lower cost, standalone and portable Spectra Retineye. Spectra is one of only three software packages certified by the English National Diabetic Retinopathy (DR) Screening Programme. It has benefitted screening providers by seamless integration with patient records and ability to monitor over time. Providers reported improved throughput and attendance.
Spectra highlights much more than just DR. In deployments to date, over 50% of urgent eye clinic referrals are for suspected non-diabetic retinopathies. Thus, Spectra detects reliable biomarkers for many conditions. The greatest causes of blindness (after cataracts) are glaucoma, age-related macular degeneration and DR. Spectra can detect early and treatable stages of these diseases, in particular low-pressure glaucoma missed by ocular pressure tests. New markets also exist for diabetic eye screening programmes (DESP) in countries lacking the resources of the UK NHS. Teleopthalmology (enabled by Spectra Retineye) could deliver these.
Both Spectra and Spectra Retineye can deliver economic benefits:
• Reducing need for expensive equipment and highly-qualified staff
• Portability
• Increased footfall in high-street optometrists from eye screening patients
• Easier and lower cost of screening to patients
• Reduced social security costs due to sight loss
Spectra will deliver tremendous social benefits. Preventable, irreversible sight damage will become rarer, reducing sickness and caring burdens. Spectra Retineye, which is eminently adaptable to teleopthalmology will allow more delivery models. These will detect more problems earlier, including the 46% of diabetics who are unaware they have diabetes and thus risk severe sight loss and other health problems until they are identified.